Propionic Acidemia Market Report 2026

Propionic Acidemia Market Overview

• Propionic Acidemia market size has reached to $2.07 billion in 2025 • Expected to grow to $2.53 billion in 2030 at a compound annual growth rate (CAGR) of 4.1% • Growth Driver: The Increase in Prevalence of Genetic Disorders Fueling the Growth of the Market Due to Rising Demand for Targeted Treatments and Early Detection • Market Trend: Innovative mRNA-Based Therapies Advancing Treatment For Rare Genetic Disorders • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Propionic Acidemia Market?

Propionic Acidemia (PA) is a rare, inherited metabolic disorder caused by a deficiency in the enzyme propionyl-CoA carboxylase, which is essential for breaking down certain amino acids and fatty acids. This deficiency leads to the accumulation of toxic compounds in the blood, causing severe symptoms such as metabolic crises, neurological damage, and, if left untreated, can be life-threatening, especially in infancy. The main drug classes of propionic acidemia are l-carnitine, antibiotics. L-Carnitine refers to a naturally occurring compound that plays a key role in the transport of long-chain fatty acids into mitochondria, where they are oxidized to produce energy. The various route of administration includes oral, intravenous, intramuscular. These are distributed through various distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies.

What Is The Propionic Acidemia Market Growth Forecast?

The propionic acidemia market size is expected to see steady growth in the next few years. It will grow to $2.53 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to increasing development of gene and enzyme therapies, rising investments in orphan drug development, expansion of precision medicine approaches, growing adoption of telemedicine for chronic care, increasing collaboration between research institutions. Major trends in the forecast period include increasing focus on early diagnosis and screening, rising adoption of personalized treatment protocols, growing research in rare metabolic disorders, expansion of specialized drug therapies, enhanced patient monitoring and management.

What Is The Driver Of The Propionic Acidemia Market?

The increasing prevalence of genetic disorders is expected to propel the growth of the propionic acidemia market going forward. Genetic disorders refer to the conditions caused by mutations or abnormalities in an individual's DNA, which can be inherited or occur spontaneously, affecting health and development. The increasing prevalence of genetic disorders is due to consanguineous marriages, as they increase the risk of inheriting recessive genetic mutations by allowing the same defective genes to be passed down from both parents, which significantly raises the likelihood of genetic conditions. Propionic acidemia enhances genetic disorder management by offering targeted treatments that address metabolic imbalances, improving patient outcomes. For instance, in February 2024, according to the Osservatorio Malattie Rare (OMAR), an Italy-based leading free, independent journalistic agency, in 2023, Italian medical centers identified 18 new disease causing genes and followed over 18, 000 patients with rare disease through regional networks. Therefore, the increasing prevalence of genetic disorders is driving the growth of the acidemia market.

Key Players In The Global Propionic Acidemia Market

Major companies operating in the propionic acidemia market report are Recordati Rare Diseases Inc, Horizon Therapeutics plc, Travere Therapeutics (Retrophin Inc), Mitsubishi Tanabe Pharma Corporation, Ultragenyx Pharmaceutical Inc, Moderna Inc, Krystal Biotech Inc, Astellas Pharma Inc, Synlogic Inc, Encoded Therapeutics Inc, BridgeBio Pharma Inc, VectivBio AG, Agios Pharmaceuticals Inc, CoA Therapeutics Inc, Imbria Pharmaceuticals Inc, Comet Therapeutics Inc, Swedish Orphan Biovitrum AB (Sobi), Regenacy Pharmaceuticals, Audentes Therapeutics, Vertex Pharmaceuticals.

Global Propionic Acidemia Market Trends and Insights

Major companies operating in the propionic acidemia market are focusing on developing innovative mRNA-based treatments to address the underlying genetic causes of the disease. mRNA therapies are a type of treatment that use messenger RNA to instruct cells to produce proteins that can prevent or treat diseases by targeting the underlying causes at a genetic level. For instance, in May 2023, Moderna, a US-based pharmaceutical and biotechnology company, presented interim data from the Phase 1/2 trial of mRNA-3927, an investigational mRNA therapy for propionic acidemia. The therapy uses mRNA to deliver functional copies of the PCCA and PCCB genes, restoring enzyme activity in the liver and potentially reducing metabolic decompensations, with this innovative treatment approach aiming to improve patient outcomes by addressing the genetic root cause of the disease, offering new hope for individuals affected by this rare metabolic disorder.

What Are Latest Mergers And Acquisitions In The Propionic Acidemia Market?

In May 2023, Ironwood Pharmaceuticals Inc., a US-based biotechnology company, acquired VectivBio for approximately $1 billion USD. With this acquisition, Ironwood aims to strengthen its rare disease pipeline by leveraging VectivBio’s novel therapies, including investigational treatments for propionic acidemia. VectivBio is a Switzerland-based biotechnology company specialized in developing treatments for rare gastrointestinal and metabolic disorders.

What Defines the Propionic Acidemia Market?

The propionic acidemia market includes revenues earned by entities through enzyme replacement therapy (ERT), nutritional therapy services, personalized care management services, patient support programs, and pharmacogenomic services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Propionic Acidemia Market Report 2026?

The propionic acidemia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the propionic acidemia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.